BridgeBio Pharma to Present New Data on Acoramidis at ESC Congress 2025

BridgeBio Pharma to present new ATTRibute-CM data at ESC Congress 2025, focusing on acoramidis for ATTR-CM treatment.

Quiver AI Summary

BridgeBio Pharma, Inc. announced that it will present new data on its drug, Acoramidis, during the European Society of Cardiology (ESC) Congress 2025 in Madrid from August 29 to September 1. This includes a rapid oral presentation on the drug's impact on reducing cardiovascular mortality from the ATTRibute-CM study, as well as two ePosters detailing its effectiveness at Month 30 in improving NT-proBNP levels and beneficial effects on ATTR stage in patients with transthyretin-mediated amyloidosis (ATTR-CM). Acoramidis is a transthyretin stabilizer aimed at reducing cardiovascular death and hospitalizations in adults with this condition. The company also shared that common adverse reactions include diarrhea and upper abdominal pain, primarily mild in nature. Founded in 2015, BridgeBio is focused on developing transformative medicines for genetic diseases.

Potential Positives

BridgeBio Pharma will present new data on Acoramidis, showcasing its potential in reducing cardiovascular mortality, which may strengthen its market position in the treatment of ATTR-CM.
The participation at the European Society of Cardiology Congress enhances visibility and credibility within the medical community, potentially attracting interest from healthcare professionals and investors.
New data from the study may provide further validation of Acoramidis's efficacy, supporting its use and possibly leading to increased adoption among physicians treating ATTR-CM patients.

Potential Negatives

Presentation of adverse reactions in the press release may raise concerns about the safety and tolerability of Attruby, which could affect physician and patient perception.
Although discontinuation rates due to adverse events were similar for Attruby and placebo, the fact that there were adverse reactions listed may lead to apprehension among stakeholders.
The press release emphasizes open-label extension data, which might indicate ongoing uncertainty or incomplete data from previous studies, potentially affecting investor confidence.

FAQ

What is BridgeBio Pharma's focus in biopharmaceuticals?

BridgeBio Pharma specializes in developing treatments for genetic diseases.

What presentation will BridgeBio give at the ESC Congress 2025?

BridgeBio will present data on Acoramidis and its impact on cardiovascular mortality at the ESC Congress.

When is the ESC Congress 2025 taking place?

The European Society of Cardiology Congress 2025 will be held from August 29 to September 1, 2025.

What is Attruby™ (acoramidis) indicated for?

Attruby is indicated for treating the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM) in adults.

What adverse reactions are associated with Attruby?

Common adverse reactions include diarrhea and upper abdominal pain, mostly mild and temporary.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$BBIO Insider Trading Activity

$BBIO insiders have traded $BBIO stock on the open market 47 times in the past 6 months. Of those trades, 0 have been purchases and 47 have been sales.

Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:

GENETIC DISORDER L.P. KKR has made 0 purchases and 2 sales selling 12,000,000 shares for an estimated $402,960,000.
GLOBAL INVESTORS LP VIKING sold 3,500,000 shares for an estimated $154,000,000
NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 23 sales selling 512,312 shares for an estimated $19,572,006.
CHARLES J HOMCY has made 0 purchases and 3 sales selling 300,000 shares for an estimated $13,912,442.
FRANK MCCORMICK sold 100,000 shares for an estimated $4,422,800
ANDREW LO sold 100,000 shares for an estimated $3,849,900
THOMAS TRIMARCHI (President and CFO) has made 0 purchases and 3 sales selling 59,590 shares for an estimated $2,961,803.
ANDREA ELLIS has made 0 purchases and 3 sales selling 57,167 shares for an estimated $2,212,683.
HANNAH VALANTINE has made 0 purchases and 6 sales selling 21,874 shares for an estimated $798,506.
BRIAN C STEPHENSON (CFO and Treasurer) has made 0 purchases and 2 sales selling 8,500 shares for an estimated $282,114.
MARICEL APULI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 2,026 shares for an estimated $84,949.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$BBIO Hedge Fund Activity

We have seen 221 institutional investors add shares of $BBIO stock to their portfolio, and 156 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

KOHLBERG KRAVIS ROBERTS & CO. L.P. removed 6,000,000 shares (-31.2%) from their portfolio in Q2 2025, for an estimated $259,080,000
VIKING GLOBAL INVESTORS LP removed 3,500,000 shares (-15.9%) from their portfolio in Q2 2025, for an estimated $151,130,000
CITADEL ADVISORS LLC removed 2,598,708 shares (-88.7%) from their portfolio in Q2 2025, for an estimated $112,212,211
FARALLON CAPITAL MANAGEMENT LLC added 2,169,000 shares (+37.8%) to their portfolio in Q2 2025, for an estimated $93,657,420
JANUS HENDERSON GROUP PLC added 2,105,133 shares (+29.4%) to their portfolio in Q2 2025, for an estimated $90,899,642
MACQUARIE GROUP LTD added 2,003,713 shares (+2189.3%) to their portfolio in Q2 2025, for an estimated $86,520,327
D. E. SHAW & CO., INC. added 1,998,104 shares (+2403.0%) to their portfolio in Q2 2025, for an estimated $86,278,130

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$BBIO Analyst Ratings

Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 13 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Cantor Fitzgerald issued a "Overweight" rating on 07/29/2025
Jefferies issued a "Buy" rating on 07/14/2025
Citigroup issued a "Buy" rating on 07/11/2025
Oppenheimer issued a "Outperform" rating on 07/09/2025
Wells Fargo issued a "Overweight" rating on 06/30/2025
B of A Securities issued a "Buy" rating on 06/25/2025
Wolfe Research issued a "Outperform" rating on 06/17/2025

To track analyst ratings and price targets for $BBIO, check out Quiver Quantitative's $BBIO forecast page.

$BBIO Price Targets

Multiple analysts have issued price targets for $BBIO recently. We have seen 14 analysts offer price targets for $BBIO in the last 6 months, with a median target of $63.5.

Here are some recent targets:

Greg Harrison from Scotiabank set a target price of $57.0 on 08/06/2025
Leland Gershell from Oppenheimer set a target price of $61.0 on 08/06/2025
Josh Schimmer from Cantor Fitzgerald set a target price of $95.0 on 07/29/2025
Danielle Brill from Truist Securities set a target price of $66.0 on 07/21/2025
Biren Amin from Piper Sandler set a target price of $68.0 on 07/14/2025
Andrew Tsai from Jefferies set a target price of $70.0 on 07/14/2025
David Lebowitz from Citigroup set a target price of $67.0 on 07/11/2025

Full Release

PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire oral presentation on additional open-label extension data from ATTRibute-CM and two ePosters with ATTRibute-CM data at Month 30 will be shared at the European Society of Cardiology (ESC) Congress 2025, taking place in Madrid, Spain from August 29 - September 1, 2025.

Oral Presentation

Acoramidis Reduces Cardiovascular Mortality (CVM): Results at Month 42 from the ATTRibute-CM Open-label Extension (OLE) Study
Presenter: Kevin Alexander, M.D., Stanford University School of Medicine, USA
Date: Saturday, August 30 at 1:15 pm CEST/7:15 am ET

ePosters:

Acoramidis-mediated Improvement in NT-proBNP at Month 30 Compared with Placebo in Patients with ATTR-CM: Results from the ATTRibute-CM Study
Presenter: Nitasha Sarswat, M.D. of UChicago Medicine, USA
Date: Sunday, August 31 at 4:15 pm CEST/10:15 am ET

Acoramidis Has a Beneficial Effect Compared with Placebo on Change from Baseline in NAC ATTR Stage at Month 30 in Patients with ATTR-CM: Results from the ATTRibute-CM Study
Presenter: Julian Gillmore, M.D., Ph.D., University College London's Centre for Amyloidosis, UK
Date: Saturday, August 29 at 3:15 pm CEST/9:15 am ET

About Attruby™ (acoramidis)
INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

About BridgeBio
BridgeBio Pharma (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn , Twitter , Facebook , and YouTube .

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
[email protected]
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
[email protected]